vs
Adaptive Biotechnologies Corp（ADPT）与EXELIXIS, INC.（EXEL）财务数据对比。点击上方公司名可切换其他公司
EXELIXIS, INC.的季度营收约是Adaptive Biotechnologies Corp的8.4倍（$598.7M vs $71.7M）。EXELIXIS, INC.净利率更高（40.8% vs -18.9%，领先59.8%）。Adaptive Biotechnologies Corp同比增速更快（51.0% vs 5.6%）。EXELIXIS, INC.自由现金流更多（$332.4M vs $1.4M）。过去两年Adaptive Biotechnologies Corp的营收复合增速更高（30.8% vs 18.7%）
ExpreS2ion Biotechnologies是一家丹麦生物技术企业，总部位于丹麦霍尔斯霍姆，专注于新型疫苗和免疫疗法产品的研发，在纳斯达克第一北增长市场瑞典板块挂牌上市。
Exelixis是一家总部位于美国加利福尼亚州阿拉米达的基因组学药物研发企业，专注于创新抗肿瘤药物开发，旗下产品Cometriq已获美国FDA批准用于治疗甲状腺髓样癌，在其余多种转移性癌症治疗领域也已展现出良好临床活性。
ADPT vs EXEL — 直观对比
营收规模更大
EXEL
是对方的8.4倍
$71.7M
营收增速更快
ADPT
高出45.4%
5.6%
净利率更高
EXEL
高出59.8%
-18.9%
自由现金流更多
EXEL
多$330.9M
$1.4M
两年增速更快
ADPT
近两年复合增速
18.7%
损益表 — Q4 2025 vs Q4 2026
| 指标 | | |
|---|---|---|
| 营收 | $71.7M | $598.7M |
| 净利润 | $-13.6M | $244.5M |
| 毛利率 | 74.6% | 95.6% |
| 营业利润率 | -17.8% | 39.3% |
| 净利率 | -18.9% | 40.8% |
| 营收同比 | 51.0% | 5.6% |
| 净利润同比 | 59.7% | 74.8% |
| 每股收益（稀释后） | $-0.08 | $0.89 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADPTEXEL
| Q1 26 | — | $598.7M | ||
| Q4 25 | $71.7M | $597.8M | ||
| Q3 25 | $94.0M | $568.3M | ||
| Q2 25 | $58.9M | $555.4M | ||
| Q1 25 | $52.4M | $566.8M | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $46.4M | $539.5M | ||
| Q2 24 | $43.2M | $637.2M |
净利润ADPTEXEL
| Q1 26 | — | $244.5M | ||
| Q4 25 | $-13.6M | $193.6M | ||
| Q3 25 | $9.5M | $184.8M | ||
| Q2 25 | $-25.6M | $159.6M | ||
| Q1 25 | $-29.9M | $139.9M | ||
| Q4 24 | $-33.7M | — | ||
| Q3 24 | $-32.1M | $118.0M | ||
| Q2 24 | $-46.2M | $226.1M |
毛利率ADPTEXEL
| Q1 26 | — | 95.6% | ||
| Q4 25 | 74.6% | 96.9% | ||
| Q3 25 | 80.7% | 96.6% | ||
| Q2 25 | 69.4% | 96.5% | ||
| Q1 25 | 67.6% | 96.5% | ||
| Q4 24 | 62.0% | — | ||
| Q3 24 | 64.1% | 96.8% | ||
| Q2 24 | 55.3% | 97.2% |
营业利润率ADPTEXEL
| Q1 26 | — | 39.3% | ||
| Q4 25 | -17.8% | 39.6% | ||
| Q3 25 | 10.9% | 37.6% | ||
| Q2 25 | -42.5% | 33.6% | ||
| Q1 25 | -56.4% | 28.8% | ||
| Q4 24 | -71.3% | — | ||
| Q3 24 | -70.3% | 25.2% | ||
| Q2 24 | -109.6% | 43.3% |
净利率ADPTEXEL
| Q1 26 | — | 40.8% | ||
| Q4 25 | -18.9% | 32.4% | ||
| Q3 25 | 10.2% | 32.5% | ||
| Q2 25 | -43.5% | 28.7% | ||
| Q1 25 | -56.9% | 24.7% | ||
| Q4 24 | -71.0% | — | ||
| Q3 24 | -69.1% | 21.9% | ||
| Q2 24 | -107.0% | 35.5% |
每股收益（稀释后）ADPTEXEL
| Q1 26 | — | $0.89 | ||
| Q4 25 | $-0.08 | $0.69 | ||
| Q3 25 | $0.06 | $0.65 | ||
| Q2 25 | $-0.17 | $0.55 | ||
| Q1 25 | $-0.20 | $0.47 | ||
| Q4 24 | $-0.22 | — | ||
| Q3 24 | $-0.22 | $0.40 | ||
| Q2 24 | $-0.31 | $0.77 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $70.5M | $1.1B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $218.8M | $2.2B |
| 总资产 | $512.7M | $2.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ADPTEXEL
| Q1 26 | — | $1.1B | ||
| Q4 25 | $70.5M | $988.5M | ||
| Q3 25 | $55.0M | $791.1M | ||
| Q2 25 | $43.2M | $1.0B | ||
| Q1 25 | $50.6M | $1.1B | ||
| Q4 24 | $47.9M | — | ||
| Q3 24 | $38.1M | $1.2B | ||
| Q2 24 | $59.8M | $1.0B |
股东权益ADPTEXEL
| Q1 26 | — | $2.2B | ||
| Q4 25 | $218.8M | $2.2B | ||
| Q3 25 | $204.4M | $2.0B | ||
| Q2 25 | $179.7M | $2.1B | ||
| Q1 25 | $190.4M | $2.2B | ||
| Q4 24 | $202.7M | — | ||
| Q3 24 | $223.8M | $2.3B | ||
| Q2 24 | $241.6M | $2.1B |
总资产ADPTEXEL
| Q1 26 | — | $2.8B | ||
| Q4 25 | $512.7M | $2.8B | ||
| Q3 25 | $490.6M | $2.7B | ||
| Q2 25 | $496.6M | $2.8B | ||
| Q1 25 | $510.9M | $2.9B | ||
| Q4 24 | $539.4M | — | ||
| Q3 24 | $558.5M | $3.0B | ||
| Q2 24 | $584.9M | $2.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.1M | $333.5M |
| 自由现金流经营现金流 - 资本支出 | $1.4M | $332.4M |
| 自由现金流率自由现金流/营收 | 2.0% | 55.5% |
| 资本支出强度资本支出/营收 | 0.9% | 0.2% |
| 现金转化率经营现金流/净利润 | — | 1.36× |
| 过去12个月自由现金流最近4个季度 | $-48.9M | $875.8M |
8季度趋势，按日历期对齐
经营现金流ADPTEXEL
| Q1 26 | — | $333.5M | ||
| Q4 25 | $2.1M | $290.3M | ||
| Q3 25 | $-7.1M | $49.0M | ||
| Q2 25 | $-12.4M | $211.4M | ||
| Q1 25 | $-28.5M | $240.3M | ||
| Q4 24 | $-12.5M | — | ||
| Q3 24 | $-27.1M | $271.3M | ||
| Q2 24 | $-17.3M | $119.5M |
自由现金流ADPTEXEL
| Q1 26 | — | $332.4M | ||
| Q4 25 | $1.4M | $288.8M | ||
| Q3 25 | $-7.5M | $46.2M | ||
| Q2 25 | $-13.1M | $208.5M | ||
| Q1 25 | $-29.7M | $236.3M | ||
| Q4 24 | $-12.6M | — | ||
| Q3 24 | $-27.4M | $263.1M | ||
| Q2 24 | $-19.0M | $113.0M |
自由现金流率ADPTEXEL
| Q1 26 | — | 55.5% | ||
| Q4 25 | 2.0% | 48.3% | ||
| Q3 25 | -8.0% | 8.1% | ||
| Q2 25 | -22.2% | 37.5% | ||
| Q1 25 | -56.7% | 41.7% | ||
| Q4 24 | -26.5% | — | ||
| Q3 24 | -59.0% | 48.8% | ||
| Q2 24 | -44.1% | 17.7% |
资本支出强度ADPTEXEL
| Q1 26 | — | 0.2% | ||
| Q4 25 | 0.9% | 0.2% | ||
| Q3 25 | 0.4% | 0.5% | ||
| Q2 25 | 1.1% | 0.5% | ||
| Q1 25 | 2.4% | 0.7% | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.7% | 1.5% | ||
| Q2 24 | 4.0% | 1.0% |
现金转化率ADPTEXEL
| Q1 26 | — | 1.36× | ||
| Q4 25 | — | 1.50× | ||
| Q3 25 | -0.75× | 0.27× | ||
| Q2 25 | — | 1.32× | ||
| Q1 25 | — | 1.72× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.30× | ||
| Q2 24 | — | 0.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
EXEL
暂无分部数据
